Universal deformation rings for the symmetric group S_4

Let k be an algebraically closed field of characteristic 2, and let W be the ring of infinite Witt vectors over k. Let S_4 denote the symmetric group on 4 letters. We determine the universal deformation ring R(S_4,V) for every kS_4-module V which has stable endomorphism ring k and show that R(S_4,V) is isomorphic to either k, or W[t]/(t^2,2t), or the group ring W[Z/2]. This gives a positive answer in this case to a question raised by the first author and Chinburg whether the universal deformation ring of a representation of a finite group with stable endomorphism ring k is always isomorphic to a subquotient ring of the group ring over W of a defect group of the modular block associated to the representation.Comment: 12 pages, 2 figure

Lichenometric dating (lichenometry) and the biology of the lichen genus rhizocarpon:challenges and future directions

Lichenometric dating (lichenometry) involves the use of lichen measurements to estimate the age of exposure of various substrata. Because of low radial growth rates and considerable longevity, species of the crustose lichen genus Rhizocarpon have been the most useful in lichenometry. The primary assumption of lichenometry is that colonization, growth and mortality of Rhizocarpon are similar on surfaces of known and unknown age so that the largest thalli present on the respective faces are of comparable age. This review describes the current state of knowledge regarding the biology of Rhizocarpon and considers two main questions: (1) to what extent does existing knowledge support this assumption; and (2) what further biological observations would be useful both to test its validity and to improve the accuracy of lichenometric dates? A review of the Rhizocarpon literature identified gaps in knowledge regarding early development, the growth rate/size curve, mortality, regeneration, competitive effects, colonization, and succession on rock surfaces. The data suggest that these processes may not be comparable on different rock surfaces, especially in regions where growth rates and thallus turnover are high. In addition, several variables could differ between rock surfaces and influence maximum thallus size, including rate and timing of colonization, radial growth rates, environmental differences, thallus fusion, allelopathy, thallus mortality, colonization and competition. Comparative measurements of these variables on surfaces of known and unknown age may help to determine whether the basic assumptions of lichenometry are valid. Ultimately, it may be possible to take these differences into account when interpreting estimated dates

Coastline shift analysis in data deficient regions: Exploiting the high spatio-temporal resolution Sentinel-2 products

In most developing countries, coastline shift monitoring using in-situ (ground-based) data faces challenges due, e.g., to data unreliability, inconsistency, deficiency, inaccessibility or incompleteness. Even where practically applicable, the traditional “boots on the ground” methods are labour intensive and expensive, thus imposing burden on poor countries struggling to meet other urgent pressing daily needs, i.e., food and medicine. Remote sensing (RS) techniques provide a more efficient and effective way of collecting data for coastline shift analysis. However, moderate spatio-temporal resolution RS products such as the widely used Landsat products (30 m and 16 days) may be insufficient where high accuracy is desired. In 2015, Sentinel-2 Multi-Spectral Instrument (MSI) remotely sensed products with higher spatio-temporal resolution (10 m and 5 days) and high spectral resolution (13 bands), which promises to improve coastline movement monitoring to high accuracy, was launched. Using two war-impacted countries (Liberia and Somalia) as case studies of regions with data deficiency or of poor quality, for the period 2015–2018, this contribution aims at (i) assessing the suitability of the new freely available high spatio-temporal Sentinel-2 products to monitor coastline shift, (ii) assessing the possibility of filling the missing Sentinel-2 gaps with Landsat 8 panchromatic band (15 m) products to provide alternative data source for mapping of coastline movements where Sentinel-2 data is unusable, e.g., due to cloud cover, and (iii), undertake a comparative analysis between Sentinel-2 (10 m), Landsat panchromatic (15 m), and Landsat multi-spectral (30 m). The results of the evaluation indicate 23% (on average) improvement gained by using Sentinel-2 compared to the traditional Landsat 30 m resolution data (i.e., 32% for Liberia and 14% for Somalia). A comparison of 100 check points from Google Earth Pro (i.e., surrogate in-situ reference data) show 91% agreement for Liberia and 85% for Somalia, indicating the potential of using Sentinel-2 data for future coastal shift studies, particularly for the data deficient regions. The results of comparative studies for Sentinel-2, Landsat panchromatic (PAN), and Landsat multi-spectral (MS) show that the percentages of Sentinel-2 and Landsat PAN that falls within 10 m threshold is much higher than Landsat MS by 35% and 26%, respectively, and for the 2016–2017 period, they provide more detailed mapping of the Liberian coastline compared to Landsat MS (30 m). Finally, panchromatic Landsat data with 15 m resolution are found to be capable of filling the missing Sentinel-2 gaps, i.e., where cloud cover hampers its usability

Track A Basic Science

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138319/1/jia218438.pd

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Systems study of the feasibility of high-level nuclear waste fractionation for thermal stress control in a geologic repository: appendices

This study assesses the benefits and costs of fractionating the cesium and strontium (Cs/Sr) components in commercial high-level waste (HLW) to a separate waste stream for the purpose of reducing geologic-repository thermal stresses in the region of the HLW. The major conclusion is that the Cs/Sr fractionation concept offers the prospect of a substantial total system cost advantage for HLW disposal if reduced HLW package temperatures in a basalt repository are desired. However there is no cost advantage if currently designated maximum design temperatures are acceptable. Aging the HLW for 50 to 100 years can accomplish similar results at equivalent or lower costs. Volume II contains appendices for: (1) thermal analysis supplement; (2) fractionation process experimental results supplement; (3) cost analysis supplement; and (4) radiological risk analysis supplement